



Australian Government

Department of Health

Office of the Gene Technology Regulator

24 October 2014

Issue of licence DIR 129 to Sugar Research Australia Ltd for a field trial of GM sugarcane

On 15 August 2014, the Gene Technology Regulator invited submissions on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) for licence application DIR 129 from Sugar Research Australia Ltd (SRA).

The Regulator has issued a licence in respect of application DIR 129, authorising the limited and controlled release (field trial) of sugarcane lines that have been genetically modified (GM) for herbicide tolerance.

The release is authorised to take place in Queensland between November 2015 and November 2021 on a maximum of 30 ha.

The primary purpose of the field trial is to evaluate the field performance of GM herbicide tolerant sugarcane. The proposed trial will be a continuation of dealings currently conducted under DIR 096 by SRA. The GM sugarcane will not enter the human food or animal feed supply.

The decision to issue the licence was made after extensive consultation on the RARMP with the public, State and Territory governments, Australian Government agencies, the Minister for the Environment, the Gene Technology Technical Advisory Committee and relevant local councils, as required by the *Gene Technology Act 2000* and the corresponding State and Territory legislation.

Issues relating to the health and safety of people and the protection of the environment raised during the consultation process were considered in the context of current scientific information in reaching the conclusions set out in the finalised RARMP and in making the decision to issue the licence.

The finalised RARMP concludes that this limited and controlled release poses negligible risks to people and the environment. Licence conditions have been imposed to restrict spread and persistence of the GMOs and their genetic material in the environment and to limit the release in size, locations and duration, as these were important considerations in the evaluation process.

Appendix A of the RARMP summarises the advice received from prescribed experts, agencies and authorities, and indicates how issues raised relating to risks to human health and safety or the environment were considered in the document. Two submissions were received from the public on the consultation RARMP and the issues raised, and their consideration, are summarised in Appendix B of the RARMP.

A Summary and the finalised RARMP, together with a set of Questions and Answers on this decision and a copy of the licence, can be obtained on-line from the [DIR 129 page](#) of the Office of the Gene Technology Regulator's website or requested via the contacts detailed below.

Office of the Gene Technology Regulator MDP 54 GPO Box 9848 CANBERRA ACT 2601

Telephone: 1800 181 030 Facsimile: 02 6271 4202 E-mail: ogtr@health.gov.au

Website: <http://www.ogtr.gov.au>